• Mutation; VGNC; VGNC:38196; ASXL1; Simple; p.Gly618fs (c.1850dupG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:40797; FBXW7; Simple; p.Arg694Gln (c.2081G>A); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:42490; KMT2C; Simple; p.Gly976fs (c.2922delG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:42491; KMT2D; Simple; p.Gln5395fs (c.16183delC); Zygosity=Homozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:43761; NF1; Simple; p.Asn58fs (c.167delA); Zygosity=Homozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:44567; PTEN; Simple; p.Lys245fs (c.734delA); Zygosity=Homozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:112756; SPEN; Simple; p.Ala8fs (c.13_14insG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:47719; TP53; Simple; p.Arg164His (c.491G>A); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=17532464; DOI=10.1016/j.leukres.2007.04.003
Kisseberth W.C., Nadella M.V.P., Breen M., Thomas R., Duke S.E., Murahari S., Kosarek C.E., Vernau W., Avery A.C., Burkhard M.J., Rosol T.J.
A novel canine lymphoma cell line: a translational and comparative model for lymphoma research.
Leuk. Res. 31:1709-1720(2007)

Patent=US7897150
Kisseberth W.C.
Canine lymphoma cell line and uses thereof.
Patent number US7897150, 01-Mar-2011

PubMed=21908323; DOI=10.1177/1040638711408064
O'Donoghue L.E., Rivest J.P., Duval D.L.
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation.
J. Vet. Diagn. Invest. 23:780-785(2011)

PubMed=23365669; DOI=10.1371/journal.pone.0054464; PMCID=PMC3554772
Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D., Modiano J.F., Cvetkovic G., Tepic S.
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.
PLoS ONE 8:E54464-E54464(2013)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=26842912; DOI=10.1111/vco.12197
Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N., Guth A., Regan D.P., Dow S.W.
Immune regulation of canine tumour and macrophage PD-L1 expression.
Vet. Comp. Oncol. 15:534-549(2017)

PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=29674676; DOI=10.1038/s41598-018-23207-7; PMCID=PMC5908872
Taher L., Beck J., Liu W., Roolf C., Soller J.T., Rutgen B.C., Hammer S.E., Chodisetti M., Sender S., Sterenczak K.A., Fuellen G., Junghanss C., Brenig B., Nolte I., Schutz E., Murua Escobar H.
Comparative high-resolution transcriptome sequencing of lymphoma cell lines and de novo lymphomas reveals cell-line-specific pathway dysregulation.
Sci. Rep. 8:6279-6279(2018)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)